показан для лечения больных с неоперабельной или метастатической меланомой

PEMBROLIZUMAB

Melanoma:Keytruda™ (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma . Non-Small Cell Lung Cancer:Keytruda is indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by a validated test with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on approved therapy for these aberrations prior to receiving Keytruda. Keytruda for NSCLC should be given to patients with Tumor Proportion Score (TPS) of 50% or greater.